Full Press Release Details
Eledon Pharmaceuticals Reports Second Quarter 2021 Operating and Financial Results
Received approval from Health Canada to initiate a clinical trial of AT-1501 in kidney transplantation; company expects to initiate trial in Q4 with initial data in late 2022
Reached agreement with the FDA to conduct a preclinical renal transplant study evaluating AT-1501 monotherapy in four non-human primates; launched academic collaboration to conduct the study with data expected mid-2022
Announces plans to develop AT-1501 as a therapy for IgA nephropathy (IgAN), the fourth potential indication for clinical development of AT-1501; company expects to initiate Phase 2 by year-end 2021
Conference call today at 4:30 PM ET
IRVINE, Calif. - Eledon Pharmaceuticals, Inc., ("Eledon") (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today reported its second quarter 2021 operating and financial results.
"We have made significant progress since the announcement in April of our updated development strategy for AT-1501 in renal transplantation," stated David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. "Enrollment in our ALS study is progressing well and we anticipate completing enrollment in the 4th quarter. Separately, we received a No Objection Letter from Health Canada in response to our Clinical Trial Application proposing to initiate a clinical trial evaluating AT-1501, in 6 to 12 subjects, replacing tacrolimus as an immunosuppressive regimen component in patients undergoing kidney transplantation. We believe that replacing tacrolimus as an agent in renal transplantation can reduce immunosuppressive side effects and improve long-term graft survival. We look forward to reporting initial clinical data from the study late next year. In addition, we plan to initiate a preclinical renal transplant study evaluating AT-1501 monotherapy in four non-human primates, as requested by the U.S. Food and Drug Administration, with data expected in mid-2022."
"In addition to our progress in ALS and renal transplant, we have selected IgA nephropathy as the fourth indication for the clinical development of AT-1501," said Steven Perrin, Ph.D., President and Chief Scientific Officer of Eledon. "There is strong scientific rationale for this indication, as blocking CD40 ligand has been shown in preclinical studies to slow disease progression and improve renal function in animal models of autoimmune nephritis. We look forward to initiating a Phase 2 trial for this fourth indication in the coming months."
Second Quarter 2021 and Recent Corporate Developments
Upcoming Anticipated Milestones
Financial Results for the Three Months Ended June 30, 2021
Eledon will hold a conference call today, August 12, 2021, at 4:30 pm Eastern Time to discuss second quarter results. The dial-in numbers are 877-407-9039 for domestic callers and 201-689-8470 for international callers. The conference ID is 13720793. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at www.eledon.com. The webcast will be archived on the website following the completion of the call.
About Eledon Pharmaceuticals and AT-1501
Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501, an anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. AT-1501 is a humanized IgG1 antibody engineered to potentially both improve safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches. The CD40L/CD40 pathway is widely recognized for its prominent role in immune regulation. CD40L is primarily expressed on activated CD4+ T cells, platelets and endothelial cells while the CD40 receptor is constitutively expressed on antigen presenting cells such as B cells, macrophages, and dendritic cells. By blocking CD40L and not the CD40 receptor, AT-1501 inhibits both the CD40 and CD11 costimulatory signaling pathways, providing the potential for improved efficacy compared to anti-CD40 receptor approaches. Blocking CD40L also increases polarization of CD4+ lymphocytes to Tregs, a specialized subpopulation of T cells that act to suppress an immune response, thus creating a more tolerogenic environment, which may also play a therapeutic role for autoimmune diseases and in the transplant setting. Eledon is headquartered in Irvine, Calif. For more information, please visit the company's website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: @Eledon_Pharma and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company's future expectations, plans and prospects, including statements about the development of product candidates, expected timing for initiation of future clinical trials, expected timing for receipt of data from clinical trials, the company's capital resources and ability to finance planned clinical trials, as well as other statements containing the words "believes," "anticipates," "plans," "expects," "estimates," "intends," "predicts," "projects," "targets," "looks forward," "could," "may," and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: risks relating to the safety and efficacy of our drug candidates; risks relating to clinical development timelines, including interactions with regulators and clinical sides, as well as patient enrollment; risks relating to costs of clinical trials and the sufficiency of the company's capital resources to fund planned clinical trials; and risks associated with the impact of the ongoing coronavirus pandemic. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and
uncertainties that could cause the company's actual results to differ significantly from the forward-looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.
LifeSci Advisors, LLC
Source: Eledon Pharmaceuticals
PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)
| June 30, 2021 | December 31, 2020 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 101,133 | $ | 114,195 | ||||
| Prepaid expenses and other current assets | 1,449 | 1,435 | ||||||
| Total current assets | 102,582 | 115,630 | ||||||
| Operating lease asset, net | 267 | 138 | ||||||
| Goodwill | 48,648 | 48,648 | ||||||
| In-process research and development | 32,386 | 32,386 | ||||||
| Other assets | 422 | 383 | ||||||
| Total assets | $ | 184,305 | $ | 197,185 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 857 | $ | 1,366 | ||||
| Current operating lease liability | 179 | 144 | ||||||
| Accrued expenses and other liabilities | 1,641 | 973 | ||||||
| Total current liabilities | 2,677 | 2,483 | ||||||
| Deferred tax liabilities | 3,017 | 4,106 | ||||||
| Non-current operating lease liability | 90 | - | ||||||
| Total liabilities | 5,784 | 6,589 | ||||||
| Commitments and contingencies (Note 5) | ||||||||
| Stockholders' equity: | ||||||||
| Series X 1 non-voting convertible preferred stock, $0.001 par value, 515,000 shares authorized; 108,070 shares issued and outstanding at June 30, 2021 and December 31, 2020 | - | - | ||||||
| Series X preferred stock, $0.001 par value, 10,000 shares authorized; 6,204 and no shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively | - | - | ||||||
| Common stock, $0.001 par value, 200,000,000 shares authorized at June 30, 2021 and December 31, 2020; 14,306,614 and 15,160,397 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively | 14 | 15 | ||||||
| Additional paid-in capital | 274,783 | 270,974 | ||||||
| Accumulated deficit | (96,276 | ) | (80,393 | ) | ||||
| Total stockholders' equity | 178,521 | 190,596 | ||||||
| Total liabilities and stockholders' equity | $ | 184,305 | $ | 197,185 |
ELEDON PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share data)
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Operating expenses | ||||||||||||||||
| Research and development | $ | 4,242 | $ | 832 | $ | 9,895 | $ | 2,480 | ||||||||
| General and administrative | 3,729 | 1,269 | 7,081 | 2,999 | ||||||||||||
| Restructuring expense | - | 490 | - | 490 | ||||||||||||
| Total operating expenses | 7,971 | 2,591 | 16,976 | 5,969 | ||||||||||||
| Loss from operations | (7,971 | ) | (2,591 | ) | (16,976 | ) | (5,969 | ) | ||||||||
| Other income (expense), net | (1 | ) | 5 | 4 | 35 | |||||||||||
| Warrant inducement expense | - | - | - | (4,829 | ) | |||||||||||
| Loss before income tax benefit | (7,972 | ) | (2,586 | ) | (16,972 | ) | (10,763 | ) | ||||||||
| Income tax benefit | 588 | - | 1,089 | - | ||||||||||||
| Net loss and comprehensive loss | $ | (7,384 | ) | $ | (2,586 | ) | $ | (15,883 | ) | $ | (10,763 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.50 | ) | $ | (2.74 | ) | $ | (1.07 | ) | $ | (11.31 | ) | ||||
| Weighted-average common shares outstanding, basic and diluted | 14,815,731 | 943,419 | 14,823,348 | 951,352 |